The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors

BACKGROUND: While immune-checkpoint inhibitors (ICIs) have transformed the field of oncology for advanced-stage cancers, they can lead to serious immune toxicities. Several systematic reviews have evaluated the risk of immune-related adverse events (irAEs); however, most have focused on published ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Karimian, Zahra, Mavoungou, Sandra, Salem, Joe-Elie, Tubach, Florence, Dechartres, Agnès
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682068/
https://www.ncbi.nlm.nih.gov/pubmed/33225901
http://dx.doi.org/10.1186/s12885-020-07518-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682068/
https://www.ncbi.nlm.nih.gov/pubmed/33225901
http://dx.doi.org/10.1186/s12885-020-07518-5

Ejemplares similares